Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29563997 | 0.79 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL27215119 | 0.74 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL29705264 | 0.74 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL30436436 | 0.74 | ALOX5AP (0.36) | DGAT1 | |
| SCHEMBL24159676 | 0.74 | ALOX5AP (0.36) | DGAT1 | |
| SCHEMBL701543 | 0.74 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL614702 | 0.72 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL16537098 | 0.72 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL29705474 | 0.71 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL27215189 | 0.71 | DGAT1 (0.36) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201165-A1 | JAK INHIBITOR COMPOUND FOR TREATING SEVERE PNEUMONIA | HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230201165-A1 | JAK INHIBITOR COMPOUND FOR TREATING SEVERE PNEUMONIA | HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230192711-A1 | JAK INHIBITOR COMPOUND AND USE THEREOF | HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192711-A1 | JAK INHIBITOR COMPOUND AND USE THEREOF | HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-06-22 | — | — | US | disclosed |
| EP-4186907-A1 | JAK INHIBITOR COMPOUND FOR TREATING SEVERE PNEUMONIA | Henan Medinno Pharmaceutical Technology Co., Ltd. (CN) | 2023-05-31 | — | — | EP | disclosed |
| EP-3932919-A1 | JAK INHIBITOR COMPOUND AND USE THEREOF | Henan Medinno Pharmaceutical Technology Co., Ltd. (CN) | 2022-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192711-A1 | JAK INHIBITOR COMPOUND AND USE THEREOF | JAK2, JAK1, JAK3 | DGAT1 3968/4885 |
| US-20230201165-A1 | JAK INHIBITOR COMPOUND FOR TREATING SEVERE PNEUMONIA | JAK1, JAK2, JAK3 | DGAT1 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.